Jeff Baxter
Chief Executive Officer en VBI VACCINES INC. .
Fortuna: 12 225 $ al 31/03/2024
Perfil
El Sr. Jeffrey R. Baxter es Presidente, Consejero Delegado y Director de VBI Vaccines, Inc., Director Independiente no Ejecutivo de Chromadex Corp., Presidente, Consejero Delegado y Director de VBI Vaccines (Delaware), Inc. y Presidente, Consejero Delegado y Director de Variation Biotechnologies (US), Inc. Es miembro del Consejo de Administración de VBI Vaccines, Inc., Chromadex Corp. y VBI Vaccines (Delaware), Inc. y Variation Biotechnologies (US), Inc. Anteriormente, el Sr. Baxter trabajó como vicepresidente senior de finanzas, operaciones, investigación y desarrollo en GlaxoSmithKline Plc, como director en British American Tobacco plc, como socio gerente en The Column Group LLC y como director en Unilever Plc. Se licenció en la Universidad de Thames Valley.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VBI VACCINES, INC.
0.09% | 27/07/2023 | 20 274 ( 0.09% ) | 12 225 $ | 31/03/2024 |
Cargos activos de Jeff Baxter
| Empresas | Cargo | Inicio |
|---|---|---|
| VBI VACCINES INC. | Chief Executive Officer | 01/05/2016 |
Variation Biotechnologies (US), Inc.
 Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Chief Executive Officer | 22/09/2009 |
VBI Vaccines (Delaware), Inc.
 VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Chief Executive Officer | 01/07/2014 |
Antiguos cargos conocidos de Jeff Baxter.
| Empresas | Cargo | Fin |
|---|---|---|
| CHROMADEX CORPORATION | Director/Board Member | 04/04/2022 |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Chief Investment Officer | 28/02/2009 |
| GSK PLC | Corporate Officer/Principal | 01/07/2006 |
| UNILEVER PLC | Corporate Officer/Principal | - |
| BRITISH AMERICAN TOBACCO P.L.C. | Corporate Officer/Principal | - |
Formación de Jeff Baxter.
| University of West London | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| BRITISH AMERICAN TOBACCO P.L.C. | Consumer Non-Durables |
| UNILEVER PLC | Consumer Non-Durables |
| GSK PLC | Health Technology |
| CHROMADEX CORPORATION | Health Technology |
| VBI VACCINES INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Health Technology |
- Bolsa de valores
- Insiders
- Jeff Baxter
